摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Ethyl 2-(8-hydroxyquinolin-5-yl)-8,9-dimethoxy-3-methyl-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carboxylate | 497961-64-5

中文名称
——
中文别名
——
英文名称
Ethyl 2-(8-hydroxyquinolin-5-yl)-8,9-dimethoxy-3-methyl-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carboxylate
英文别名
——
Ethyl 2-(8-hydroxyquinolin-5-yl)-8,9-dimethoxy-3-methyl-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carboxylate化学式
CAS
497961-64-5
化学式
C27H26N2O5
mdl
——
分子量
458.514
InChiKey
KILMQYUASQYHIY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    34
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    82.8
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10
    申请人:Gopalan Balasubramanian
    公开号:US20090281131A1
    公开(公告)日:2009-11-12
    The present invention relates to novel heterocyclic compounds that are useful as phosphodiesterase inhibitors (PDEs) in particular phosphodiesterase type 4 (PDE IV) inhibitors and phosphodiesterase type 10 (PDE 10) inhibitors, processes for their preparation, pharmaceutical compositions containing them and their use in treating allergic and inflammatory diseases as well as for inhibiting the production of Tumor Necrosis Factor (TNF-α).
    本发明涉及一种新型杂环化合物,其作为磷酸二酯酶抑制剂(PDEs),特别是磷酸二酯酶4型(PDE IV)抑制剂磷酸二酯酶10型(PDE 10)抑制剂,其制备方法,含有它们的制药组合物以及它们在治疗过敏和炎症性疾病以及抑制肿瘤坏死因子(TNF-α)的产生中的用途。
  • Methods for treating diabetes and related disorders using pde10a inhibitors
    申请人:Sweet Laurel
    公开号:US20070032404A1
    公开(公告)日:2007-02-08
    The methods of the invention relate to the treatment of diabetes, including type 2 diabetes, and related disorders by administration of a PDE10A inhibitor. Such PDE10A inhibitors may be administered in conjunction with alpha-glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compounds, B-3 agonist, or insulin. Such PDE10A inhibitors may also be administered in conjunction with body weight reducing agents. Further methods of the invention relate to stimulating insulin release from pancreatic cells, for example, in response to an elevation in blood glucose concentration, by administration of a PDE10A inhibitor.
  • US8263648B2
    申请人:——
    公开号:US8263648B2
    公开(公告)日:2012-09-11
查看更多